Company Overview of Hetero Drugs Limited
Hetero Drugs Limited, a pharmaceutical company, develops, manufactures, and markets active pharmaceutical ingredients (APIs), intermediate chemicals, and generic finished dosages in India. The company offers APIs in the areas of antiretroviral and oncology products to the global pharmaceutical market; finished dosages in various therapeutic areas, including antiretroviral, gastro-intestinal, cardiovascular, antidepressants/antipsychotics, anti-diabetics, pain management, anti-infectives, dermatology, and oncology; and oncology products, including injectables, solid/liquid oral dosages, ointments, soft gelatine capsules, and inhalers. It also develops and manufactures bio-generics; and provid...
HETERO CORPORATE INDUSTRIAL ESTATES
Founded in 1993
Key Executives for Hetero Drugs Limited
Founder, Chairman and Managing Director
Director of Production and Whole Time Director
Compensation as of Fiscal Year 2015.
Hetero Drugs Limited Key Developments
Cipla Reportedly Mulls Acquisition Of Hetero’s US Business
Sep 3 15
Cipla Limited (NSEI:CIPLA) is in talks to acquire US business of Hetero Drugs Limited, which is run under the Camber Pharmaceuticals brand, according to sources. The deal, which may be announced in the next few days, values Hetero's US business at $500-550 million and may including manufacturing facilities, sources added. When contacted by CNBC-TV18, Cipla said that it did not want to comment on any product or partner discussions and that it was "constantly in discussions with multiple partners on potential collaborations". "Our aspiration is to drive access to and ensure availability of affordable medicines," Cipla said.
Hetero Announces the Launch of Biosimilar Rituximab MABALL in India
Aug 5 15
Hetero Group announced the successful launch of its biosimilar 'Rituximab' under the brand name MABALL in India. The launch of biosimilar Rituximab will provide a much needed access to patients in India suffering with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL). Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths - 100mg/10ml and 500mg/50ml.
Dr Reddy's Laboratories Enters into an Agreement with Hetero to Market Hepatitis C Drug Sofosbufir 400 mg Tablets
Mar 24 15
Dr Reddy's Laboratories announced it has entered into an agreement with Hetero to allow the company to distribute and market chronic Hepatitis C drug Sofosbufir 400 mg tablets, manufactured by Hetero, under the brand name Resof in India. Clinical studies have indicated that Sofosbuvir 400 mg in combination with other agents achieved high cure rates while shortening treatment duration to 12 weeks and reducing or completely eliminating the need for Interferon injections, depending on the viral genotype. According to the World health Organization, close to 12 million Indians suffer from chronic Hepatitis C, a disease that can seriously affect the liver, leading to potentially lifethreatening complications, including liver cancer. Earlier this month, two citybased pharma players, Natco Pharma Limited and Hetero, got approval to manufacture and market generic Sofosbuvir tablets 400 mg, from the Drugs Controller General of India. Sofosbuvir is sold globally by Gilead Sciences Inc. under the Sovaldi brand name. Both the Indian companies had announced that they will market generic Sofosbuvir at a price of INR 19,900 for a bottle of 28 tablets.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|